Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adverum Biotechnologies, Inc.ADVM · Entity 71889 | SVP, Chief Medical Officer | February 15, 2018 | February 20, 2018 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | June 02, 2026 | June 04, 2026 |
| Cardiff Oncology, Inc.TROV · Entity 6917 | Director | June 20, 2019 | June 24, 2019 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP and Chief Medical Officer | February 22, 2017 | February 24, 2017 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Director | June 16, 2026 | June 18, 2026 |
| Passage BIO, Inc.PASG · Entity 7829 | Director | May 19, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adverum Biotechnologies, Inc.
Report date February 15, 2018 · Filed February 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.40 · Expires 2028-02-14 | Direct | 160,000 |
Reported balance
After 2018-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-15 · Grant · Acquired 160,000 · Balance 160,000 F1: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 15, 2018 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 15, 2018 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.
BIOMARIN PHARMACEUTICAL INC
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,040 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Grant · Acquired 7,490 · Balance 21,040 F1: Restricted stock units granted on June 2, 2026. Price not applicable. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on June 2, 2026. Price not applicable.
Cardiff Oncology, Inc.
Report date June 20, 2019 · Filed June 24, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.48 · Expires 2029-06-20 | Direct | 46,019 |
Reported balance
After 2019-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 44,734 · Balance 46,019 |
HALOZYME THERAPEUTICS, INC.
Report date February 22, 2017 · Filed February 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $12.07 · Expires 2027-02-22 | Direct | 72,925 |
Reported balance
After 2017-02-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-22 · Grant · Acquired 72,925 · Balance 72,925 F1: This option vests one-fourth on such date and then 1/48th monthly thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 45,568 |
Reported balance
After 2017-02-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-22 · Grant · Acquired 45,568 · Balance 45,568 F2: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests one-fourth on such date and then 1/48th monthly thereafter.
F2: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter.
IOVANCE BIOTHERAPEUTICS, INC.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 90,316 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 90,316 · Balance 90,316 F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended). F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred restricted stock unit ("DRSU") represents a contingent right to receive one share of the Issuer's common stock and are granted pursuant to the Issuer's 2018 Equity Incentive Plan (as amended).
F2: Provided the Reporting Person continues to be providing service to the Issuer on the following dates, the DRSUs shall vest on the earlier of: (i) the first anniversary of the Transaction Date; or (ii) the day prior to the Issuer's next annual shareholder meeting. Notwithstanding the vesting, the issuance of the common stock will be deferred until the earlier of (i) three months after the Reporting Person's resignation or removal from the Board of Directors or no longer providing service because of death or disability, (ii) a change in control (as defined in the DRSU agreement) or (iii) ten years from the Transaction Date.
Passage BIO, Inc.
Report date May 19, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2036-05-19 | Direct | 10,539 |
Reported balance
After 2026-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-19 · Grant · Acquired 10,539 · Balance 10,539 F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2027 Annual Meeting of its stockholders, subject to the reporting person's continuous service to the issuer on such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 110,959 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount. F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law. F3: Includes 629 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2028-06-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 173,389 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.20 · Expires 2028-06-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Disposition to issuer · Disposed 67,575 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.12 · Expires 2028-11-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 989,971 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.43 · Expires 2029-02-19 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-17 · Disposition to issuer · Disposed 155,844 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.33 · Expires 2030-01-05 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-08-17 · Disposition to issuer · Disposed 325,000 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $140.01 · Expires 2031-02-07 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-08-17 · Disposition to issuer · Disposed 101,775 · Balance 0 F5: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.68 · Expires 2032-02-08 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-08-17 · Disposition to issuer · Disposed 224,640 · Balance 0 F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for $76.00 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the Cash Amount.
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU") whether vested or unvested was cancelled and converted into the right to receive cash, without interest, in an amount equal to $76.00 per Share issuable in settlement of such RSU immediately before the effective time of the Merger, net of any withholding taxes required to be deducted and withheld by applicable law.
F3: Includes 629 shares acquired on June 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan.
F4: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
F5: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price equal to or greater than $76.00, was cancelled without any consideration in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2021 Filed Feb 10, 2021 22:52 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 22,617 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-009357 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,195 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. F2 · balance_after: Includes 369 shares acquired by the Reporting Person on June 10, 2020 pursuant to the Issuer's Employee Stock Purchase Plan (the "ESPP") and 337 shares acquired on December 10, 2020 pursuant the ESPP. Read SEC document |
| June 08, 2020 Filed Jun 11, 2020 00:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $32.17 | $0.00 |
DisclosureSEC source: 0001104659-20-072137 · tm2022303d1_4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-07 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant, such that the options will be fully vested and exercisable on June 8, 2021. Read SEC document |
| May 21, 2020 Filed May 26, 2020 21:55 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | PurchaseCommon Stock | 4,166 | $60.00 | $249,960.00 |
DisclosureSEC source: 0001209191-20-032143 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,872 F1 · kind: The shares were purchased in connection with the Issuer's public offering. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 00:26 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 10,000 | $14.98 | $149,750.00 |
DisclosureSEC source: 0001209191-20-021188 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,900 F1 · price: Represents the weighted average purchase price per share. The shares were purchased at prices ranging from $14.79 to $15.00 per share. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 03, 2020 Filed Mar 3, 2020 23:37 UTC | Passage BIO, Inc. PASG · Entity 7829 | PurchaseCommon Stock | 8,900 | $18.00 | $160,200.00 |
DisclosureSEC source: 0001209191-20-015619 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,900 Read SEC document |
| February 27, 2020 Filed Mar 2, 2020 23:05 UTC | Passage BIO, Inc. PASG · Entity 7829 | GrantDirector Stock Option (Right to Buy) · Derivative | 33,836 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014706 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,836 Underlying: Common Stock · 33,836 shares Expires 2030-02-27 F1 · derivative.exercise_date: The option vests as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 21:24 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 325,000 | $0.00 Strike: $63.33 | $0.00 |
DisclosureSEC source: 0001209191-20-002517 · doc4.xml · derivative · entry 2 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2030-01-05 F2 · derivative.exercise_date: 1/48th of the shares will vest each month following January 6, 2020, so that all of the shares are vested four (4) years after January 6, 2020. Read SEC document |
| December 10, 2019 Filed Jan 8, 2020 21:24 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantCommon Stock | 706 | $31.13 | $21,975.66 |
DisclosureSEC source: 0001209191-20-002517 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,706 F1 · kind: The Reporting Person acquired 706 shares on December 10, 2019 at $31.127 per share pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 20:15 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | PurchaseCommon Stock | 10,000 | $45.00 | $450,000.00 |
DisclosureSEC source: 0001209191-19-049146 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · kind: The shares were purchased in connection with the Issuer's public offering. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 20:05 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 44,734 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0000899243-19-017916 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,019 Underlying: Common Stock · 44,734 shares Expires 2029-06-20 Read SEC document |
| June 10, 2019 Filed Jun 11, 2019 21:16 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $19.93 | $0.00 |
DisclosureSEC source: 0001144204-19-030593 · tv523378_4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-06-09 F1 · derivative.exercise_date: These options are exercisable in four equal quarterly installments of 8,750 each following the date of grant. If the Reporting Person's service to the Issuer terminates before the expiration date, the option shares will be exercisable for two years following termination of service, unless the Reporting Person is terminated for cause, in which case the options shall terminate immediately. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 21:55 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | PurchaseCommon Stock | 12,000 | $18.00 | $216,000.00 |
DisclosureSEC source: 0001209191-19-025786 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 F1 · kind: The shares were purchased at the Issuer's initial public offering. Read SEC document |
| February 15, 2018 Filed Feb 20, 2018 19:16 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $6.40 | $0.00 |
DisclosureSEC source: 0001209191-18-011601 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of February 15, 2018 (the "Vesting Commencement Date"), and 1/48 of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 22:00 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001901 · doc4.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,428 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 18:11 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantStock Option (Right to Buy) · Derivative | 213,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001209191-17-041253 · doc4.xml · derivative · entry 2 Countouriotis Athena · CIK 0001571469 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,000 Underlying: Common Stock · 213,000 shares Expires 2027-06-18 F2 · derivative.exercise_date: Twenty-five percent (25%) of the total shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48 of the total shares subject to the option shall vest and become exercisable each month thereafter, such that all of the shares subject to the option shall be vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| June 19, 2017 Filed Jun 21, 2017 18:11 UTC | Adverum Biotechnologies, Inc. ADVM · Entity 71889 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041253 · doc4.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock of the Issuer for each one (1) RSU upon the vesting thereof. Such RSUs vest with respect to twenty-five percent (25%) of the shares subject thereto on each anniversary of June 19, 2017 (the "Vesting Commencement Date"), such that all of the shares subject to the RSUs shall be vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 45,568 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-003119 · edgar.xml · derivative · entry 2 Countouriotis Athena · CIK 0001571469 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,568 Underlying: Common Stock · 45,568 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 72,925 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001179110-17-003119 · edgar.xml · derivative · entry 1 Countouriotis Athena · CIK 0001571469 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,925 Underlying: Common Stock · 72,925 shares Expires 2027-02-22 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 18,496 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001809 · edgar.xml · derivative · entry 3 Countouriotis Athena · CIK 0001571469 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,487 Underlying: Common Stock · 18,496 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 6,900 | $12.26 | $84,594.00 |
DisclosureSEC source: 0001179110-17-001809 · edgar.xml · nonDerivative · entry 2 Countouriotis Athena · CIK 0001571469 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,077 F1 · shares: The reported disposition of 6,900 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 18,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001809 · edgar.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,977 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 21:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-000756 · edgar.xml · derivative · entry 2 Countouriotis Athena · CIK 0001571469 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F1 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| January 05, 2017 Filed Jan 9, 2017 21:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-000756 · edgar.xml · nonDerivative · entry 1 Countouriotis Athena · CIK 0001571469 · SVP and Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.